A week after Japan’s Black Monday moment re-introduced panic to the markets, Akamai (AKAM) may trend higher. Last Friday, the firm jumped by 10.9% after posting quarterly results.
In Q2, Akamai earned $1.58 (non-GAAP) per share after revenue increased by 4.7% Y/Y to $980 million. Though its growth is not impressive, analysts remained positive. They maintained their price targets and outlook for the security firm. Demand for computing is also an upside driver for profit margins.
After Moody’s Ratings downgraded Intel’s (INTC) debt, shares fell again below $20.00. Moody’s cut its rating for its senior unsecured ratings from Baa1, down from A3. The firm cited expectations of weaker profitability over the next 12 to 18 months. Intel has higher costs associated with its production and manufacturing processes.
Investors may ignore the lawsuit against Intel since lawyers will earn the most if the court sides in favor of the plaintiff.
Watch Insulet (PODD) today. Shares peaked at $200, closing last week at $182.19. On August 8, it posted a non-GAAP EPS of $0.55. Revenue increased by 23.2% Y/Y to $488.5 million. Investors may consider Insulet’s peers. This includes DexCom (DXCM), Tandem Diabetes (TNDM), Teleflex (TFX), and Penumbra (PEN).
